Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough

Last updated: May 31, 2016
Sponsor: Novartis
Overall Status: Completed

Phase

2

Condition

Acute Rhinitis

Common Cold

Treatment

N/A

Clinical Study ID

NCT02379637
2160-A-201
  • Ages 18-65
  • All Genders

Study Summary

This study is designed to improve knowledge regarding the initial effectiveness of N-acetylcysteine (NAC) on cold and cough symptoms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Cold/URTI symptoms occurring no more than 4 days

  • cough due to a cold or acute viral (URTI) with an onset of no more than 3 days

  • cough frequency with specified cut-off

Exclusion

Exclusion Criteria:

  • A subchronic, or chronic cough (cough duration > 2 months) due to any condition otherthan a cold/URTI

  • Diagnosed as suffering from any pulmonary conditions associated with cough, e.g.,chronic obstructive pulmonary disease (COPD), acute or chronic bronchitis, asthma,cystic fibrosis

  • Taking any medications known to induce cough

  • Fever of greater than 39°C (102°F) orally

  • Complication of the common cold like otitis media, severe sinusitis, or pneumonia

  • Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Total Participants: 70
Study Start date:
January 01, 2015
Estimated Completion Date:
April 30, 2015

Connect with a study center

  • Chicoutimi, Quebec
    Canada

    Site Not Available

  • Montreal, Quebec
    Canada

    Site Not Available

  • Sherbrook, Quebec
    Canada

    Site Not Available

  • Victoriaville, Quebec
    Canada

    Site Not Available

  • Quebec,
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.